Medical Oncologist
HER2-positive breast cancer
The full HER2 treatment pathway: what the year looks like
Treatment for early HER2-positive breast cancer usually runs for about a year, combining chemotherapy and HER2-targeted drugs with surgery, radiation where needed, and continued targeted treatment. This page explains, in general terms, how the year often unfolds and the checks that run alongside.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What does a year of HER2-positive treatment usually involve?
- How the year often unfolds
- The main parts of HER2-positive treatment
- The checks that run alongside treatment
- The vocabulary, in plain language
- What to expect honestly
- Planning daily life around a year of treatment
- What happens once HER2 treatment ends
- What people assume about HER2-positive treatment
- Common questions about the HER2 pathway
The short answer
What does a year of HER2-positive treatment usually involve?
Treatment for early HER2-positive breast cancer usually runs for about a year. It commonly combines chemotherapy with HER2-targeted drugs such as trastuzumab, often with pertuzumab added, followed by surgery, radiation where needed, and continued HER2-targeted treatment to complete the year. If the cancer is also hormone-sensitive, hormone therapy is added and continues for several years.
Why the year is structured this way
HER2-positive cancers can grow quickly, but they respond very well to targeted drugs. Combining these with chemotherapy, and continuing them after surgery, has greatly improved outcomes for this type of breast cancer.
Treatment before or after surgery
Many women have chemotherapy and targeted drugs before surgery, which shows how the cancer responds. That response then shapes which targeted treatment is used afterwards.
When the pathway is different
Very small cancers may be treated with a lighter regimen, and people with heart problems may need adjustments. Metastatic HER2-positive cancer follows a different, ongoing pathway.
This page gives general information only. Your own pathway is planned by your oncologist.The year at a glance
How the year often unfolds
A common sequence when treatment starts before surgery. Your own plan may differ in order or length.
-
The first few months: chemotherapy with targeted drugs
Chemotherapy is given in cycles alongside trastuzumab and often pertuzumab. Scans or examinations check that the cancer is shrinking.
-
A few weeks after chemotherapy: surgery
Lumpectomy or mastectomy, with lymph node surgery. The tissue removed shows whether any cancer remains.
-
After surgery: radiation where needed
Radiation is often given after lumpectomy and in some cases after mastectomy. HER2-targeted treatment usually continues during this time.
-
The rest of the year: continuing targeted treatment
Targeted injections or infusions continue every few weeks to complete about a year in total. If cancer remained at surgery, a different targeted drug may be used.
-
Beyond the year: hormone therapy and follow-up
For hormone-sensitive cancers, hormone tablets continue for several years. Regular follow-up appointments continue after treatment ends.
The treatments
The main parts of HER2-positive treatment
Each part does a different job. Most women receive several of them.
Trastuzumab
An antibody that attaches to the HER2 protein on cancer cells and blocks its growth signals. It is the foundation of HER2-targeted treatment and is available as biosimilars in India.
Pertuzumab
A second antibody that attaches to HER2 at a different site. Added to trastuzumab in some higher-risk situations to strengthen the effect.
Not every woman needs it.Trastuzumab emtansine
Trastuzumab joined to a chemotherapy drug. Used after surgery when cancer remained despite treatment beforehand.
Chemotherapy
Given alongside the targeted drugs, usually a taxane with or without other drugs. It works together with the antibodies.
Sometimes added
- Hormone therapy for hormone-sensitive cancers
- Neratinib in selected situations
- Radiation after surgery
Keeping you safe
The checks that run alongside treatment
A heart scan before starting
An echocardiogram or similar scan measures how well your heart pumps, because HER2-targeted drugs can occasionally affect heart function.
Repeat heart scans
The scan is repeated every few months during treatment. Most changes are mild and recover if treatment is paused or adjusted.
Blood tests before each cycle
Counts, liver and kidney function are checked, particularly during chemotherapy.
Checking the response
Examinations or scans during treatment before surgery, and the pathology report after surgery, show how well the cancer responded.
Reporting symptoms
Breathlessness, swollen ankles or a racing heart should be reported promptly, as they may point to a heart effect.
Words you will hear
The vocabulary, in plain language
- HER2
- A protein on some breast cancer cells that drives growth. Cancers with a lot of it are called HER2-positive.
- Targeted therapy
- Drugs that act on a specific feature of cancer cells, such as the HER2 protein.
- Neoadjuvant
- Treatment given before surgery.
- Pathological complete response
- No invasive cancer found in the tissue removed at surgery after treatment beforehand.
- Residual disease
- Cancer still present at surgery after treatment beforehand.
- Ejection fraction
- A measure of how well the heart pumps, checked with heart scans during treatment.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
What to expect honestly
HER2-positive breast cancer was once considered one of the harder types to treat. Targeted drugs have changed that, and outcomes for early HER2-positive cancer are now much better. Treatment is long and demanding, though, and the year can feel very tiring.
The year is a commitment
Regular hospital visits for injections or infusions continue long after chemotherapy ends. Planning work and family life around this schedule helps.
Heart effects are usually manageable
Changes in heart function are uncommon and usually recover. Regular scans exist to catch them early. Treatment may be paused and restarted once the heart recovers.
Cost is a real concern
HER2-targeted drugs can be expensive, though biosimilars have made trastuzumab more affordable in India. Ask your team early about costs and what support may be available.
What this page cannot tell you
It cannot tell you which drugs and sequence you will receive. Ask your oncologist for a written outline of your year.
Living through the year
Planning daily life around a year of treatment
A year is a long time to be in treatment. Thinking ahead about the practical side makes it easier to keep going.
Work
Many women reduce their hours or take leave during chemotherapy, then return while continuing targeted treatment. Share your schedule with your employer early.
Travel to treatment
Targeted treatment continues every few weeks for months. If travel is difficult, ask whether any part can be given closer to home or as an injection under the skin.
Energy and rest
Tiredness often lingers after chemotherapy ends. Gentle exercise, good sleep and accepting help usually do more than pushing through.
After the year
What happens once HER2 treatment ends
Finishing a year of treatment is a major milestone, and many women feel a mix of relief and worry when the regular visits stop.
Follow-up continues
You will still see your team regularly for examinations and yearly mammograms. Tell them about any new symptoms between visits rather than waiting.
Recovery takes time
Energy often returns gradually over the following months. Gentle exercise, good sleep and support from family and survivor groups help many women find their footing again.
Commonly believed
What people assume about HER2-positive treatment
HER2-positive means the worst kind of breast cancer.
HER2-positive cancers can grow quickly, but they respond very well to targeted drugs. With modern treatment, outcomes for early HER2-positive cancer are much better than they once were.
Once chemotherapy finishes, treatment is over.
HER2-targeted treatment usually continues after chemotherapy to complete about a year. Stopping early can reduce its benefit.
Biosimilar trastuzumab is a weaker copy.
Approved biosimilars are tested to show they work in a comparable way to the original. Ask your oncologist about the product planned for you.
A heart scan change means treatment must stop for good.
Most changes are mild and recover. Treatment is often paused and restarted once heart function improves.
Questions we are asked
Common questions about the HER2 pathway
Why does HER2 treatment last a year?
Large studies found that a year of trastuzumab gave a strong benefit, and this became the standard. Shorter courses have been studied, and your oncologist can explain what applies to you.
Will I lose my hair?
Hair loss is common during the chemotherapy part. The targeted drugs on their own do not usually cause hair loss, so hair often regrows while targeted treatment continues.
Can trastuzumab be given as an injection?
In many centres it is available as an injection under the skin, which is quicker than an infusion. Ask whether this option is available to you.
What if cancer remains after surgery?
A different targeted drug, trastuzumab emtansine, is often used after surgery in that situation. Your oncologist will explain the change.
Do I need hormone therapy as well?
If your cancer is also hormone receptor positive, yes, usually for several years. It is often started after chemotherapy and alongside targeted treatment.
Can I work during the year?
Many women work during part of it, especially once chemotherapy ends. Discuss the schedule with your team and employer.
How often are heart scans done?
Usually before treatment and every few months during it. Your team sets the schedule based on your health and the drugs you receive.
Where can I read about my own drugs?
Your oncology team will give you written information about each drug in your plan. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Targeted cancer drugs for breast cancer
- National Cancer Institute — Breast cancer treatment (PDQ)
- Breast Cancer Now — HER2-positive breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.